Terms: = Ovarian cancer AND ACVR2A, ACVR2, 92, ENSG00000121989, ACTRII, P27037 AND Treatment
714 results:
1. Assessment of secular trends of three major gynecologic cancers burden and attributable risk factors from 1990 to 2019: an age period cohort analysis.
Liu Y; Shi W; Mubarik S; Wang F
BMC Public Health; 2024 May; 24(1):1349. PubMed ID: 38764017
[TBL] [Abstract] [Full Text] [Related]
2. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant ovarian cancer: Findings From Cohort A of the OPAL Phase II Trial.
Liu JF; Gaillard S; Wahner Hendrickson AE; Yeku O; Diver E; Gunderson Jackson C; Arend R; Ratner E; Samnotra V; Gupta D; Chung J; Zhang H; Compton N; Baines A; Bacqué E; Liu X; Felicetti B; Konecny GE
JCO Precis Oncol; 2024 May; 8():e2300693. PubMed ID: 38754056
[TBL] [Abstract] [Full Text] [Related]
3. Anxiety Levels in Brazilian Women with Metastatic Breast cancer Undergoing Palliative Chemotherapy: A Prospective Study.
Marcondes L; Silva LDS; Ribeiro CO; Oshiro NN; Nogueira LA; Guimaraes PRB; Kalinke LP
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1135-1141. PubMed ID: 38679972
[TBL] [Abstract] [Full Text] [Related]
4. Common misconceptions and myths about ovarian cancer causation: a national cross-sectional study from palestine.
Elshami M; Jaber I; Alser M; Al-Slaibi I; Jabr H; Ubaiat S; Tuffaha A; Khader S; Khraishi R; Arafeh ZA; Al-Madhoun S; Alqattaa A; Yaseen A; El Hadi AA; Barhoush O; Hijazy M; Eleyan T; Alser A; Hziema AA; Shatat A; Almakhtoob F; Mohamad B; Farhat W; Abuamra Y; Mousa H; Adawi R; Musallam A; Albarqi SI; Abu-El-Noor N; Bottcher B
BMC Public Health; 2024 Apr; 24(1):1027. PubMed ID: 38609950
[TBL] [Abstract] [Full Text] [Related]
5. Tumor-Infiltrating Lymphocytes in Triple-Negative Breast cancer.
Leon-Ferre RA; Jonas SF; Salgado R; Loi S; de Jong V; Carter JM; Nielsen TO; Leung S; Riaz N; Chia S; Jules-Clément G; Curigliano G; Criscitiello C; Cockenpot V; Lambertini M; Suman VJ; Linderholm B; Martens JWM; van Deurzen CHM; Timmermans AM; Shimoi T; Yazaki S; Yoshida M; Kim SB; Lee HJ; Dieci MV; Bataillon G; Vincent-Salomon A; André F; Kok M; Linn SC; Goetz MP; Michiels S;
JAMA; 2024 Apr; 331(13):1135-1144. PubMed ID: 38563834
[TBL] [Abstract] [Full Text] [Related]
6. Clinicopathological features and surgical procedures of adnexal masses with abdominal pain in pediatric and adolescent patients.
Liu Q; Li Z; Zhou H; Cao D; Yang J; Shen K; Lang J
Orphanet J Rare Dis; 2024 Mar; 19(1):132. PubMed ID: 38515195
[TBL] [Abstract] [Full Text] [Related]
7. Small-molecule inhibitor HI-TOPK-032 improves NK-92MI cell infiltration into ovarian tumours.
Deng M; Yang R; Sun Q; Zhang J; Miao J
Basic Clin Pharmacol Toxicol; 2024 May; 134(5):629-642. PubMed ID: 38501576
[TBL] [Abstract] [Full Text] [Related]
8. A clinicopathological study about the epidemiology of granulosa cell tumors in Lebanon.
Yaacoub S; Hajj L; Khairallah A
BMC Cancer; 2024 Mar; 24(1):309. PubMed ID: 38448917
[TBL] [Abstract] [Full Text] [Related]
9. Platinum desensitization therapy and its impact on the prognosis of ovary high-grade serous adenocarcinoma: a real world-data.
Li K; Yin R
Front Immunol; 2024; 15():1346464. PubMed ID: 38312839
[TBL] [Abstract] [Full Text] [Related]
10. The comparison of functional status and health-related parameters in ovarian cancer survivors with healthy controls.
Gultekin SC; Cakir AB; Guc ZG; Ozalp FR; Keskinkilic M; Yavuzsen T; Yavuzsen HT; Karadibak D
Support Care Cancer; 2024 Jan; 32(2):119. PubMed ID: 38252310
[TBL] [Abstract] [Full Text] [Related]
11. Impacts of ovarian reserve on conservative treatment for endometrial cancer and atypical hyperplasia.
Wu P; Shan W; Xue Y; Wang L; Liu S; Chen X; Luo X
Front Endocrinol (Lausanne); 2023; 14():1286724. PubMed ID: 38250737
[TBL] [Abstract] [Full Text] [Related]
12. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.
Wang Y; Dackus GMHE; Rosenberg EH; Cornelissen S; de Boo LW; Broeks A; Brugman W; Chan TWS; van Diest PJ; Hauptmann M; Ter Hoeve ND; Isaeva OI; de Jong VMT; Jóźwiak K; Kluin RJC; Kok M; Koop E; Nederlof PM; Opdam M; Schouten PC; Siesling S; van Steenis C; Voogd AC; Vreuls W; Salgado RF; Linn SC; Schmidt MK
BMC Med; 2024 Jan; 22(1):9. PubMed ID: 38191387
[TBL] [Abstract] [Full Text] [Related]
13. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors.
How JA; Legarreta AF; Handley KF; Fellman B; Foster KI; Glassman D; Vuttaradhi VK; Brodsky AL; Lawson B; Frumovitz M; Westin SN; Ramondetta LM; Gershenson DM; Sood AK; Hillman RT
Am J Obstet Gynecol; 2024 May; 230(5):544.e1-544.e13. PubMed ID: 38191019
[TBL] [Abstract] [Full Text] [Related]
14. Comparative analysis of doublet chemotherapy regimens plus bevacizumab in patients with recurrent ovarian cancer.
Khanmammadov NJ; Doğan İ; Okay NS; Azizy A; Saip P; Aydiner A
Medicine (Baltimore); 2024 Jan; 103(1):e36750. PubMed ID: 38181291
[TBL] [Abstract] [Full Text] [Related]
15. Phthalimide-tethered isatins as novel poly(ADP-ribose) polymerase inhibitors: Design, synthesis, biological evaluations, and molecular modeling investigations.
El Hassab MA; El-Hafeez AAA; Almahli H; Elsayed ZM; Eldehna WM; Hassan GS; Abou-Seri SM
Arch Pharm (Weinheim); 2024 Mar; 357(3):e2300599. PubMed ID: 38100160
[TBL] [Abstract] [Full Text] [Related]
16. Significance of Ultra-Radical Surgery in Extensive Metastatic ovarian Growing Teratoma Syndrome.
Li S; Wang T; Du H; Tang H; Zhang T; Zhang R; Zhang X; Yang J
Oncology; 2023; 101(12):773-781. PubMed ID: 38096801
[TBL] [Abstract] [Full Text] [Related]
17. ovarian cancer disease burden decreased in the United States from 1975 to 2018: A joinpoint and age-period-cohort analysis.
He J; Hu Q
Medicine (Baltimore); 2023 Dec; 102(48):e36029. PubMed ID: 38050303
[TBL] [Abstract] [Full Text] [Related]
18. Oncologic outcomes of robot-assisted laparoscopy versus conventional laparoscopy for the treatment of apparent early-stage endometrioid adenocarcinoma of the uterus.
Lim YH; Dagher C; Abu-Rustum NR; Mueller JJ; Sonoda Y; Zivanovic O; Broach V; Leitao MM
Gynecol Oncol; 2023 Dec; 179():152-157. PubMed ID: 37980770
[TBL] [Abstract] [Full Text] [Related]
19. Olaparib plus Durvalumab, with or without Bevacizumab, as treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed ovarian cancer: A Phase II Multi-Cohort Study.
Drew Y; Kim JW; Penson RT; O'Malley DM; Parkinson C; Roxburgh P; Plummer R; Im SA; Imbimbo M; Ferguson M; Rosengarten O; Steeghs N; Kim MH; Gal-Yam E; Tsoref D; Kim JH; You B; De Jonge M; Lalisang R; Gort E; Bastian S; Meyer K; Feeney L; Baker N; Ah-See ML; Domchek SM; Banerjee S;
Clin Cancer Res; 2024 Jan; 30(1):50-62. PubMed ID: 37939124
[TBL] [Abstract] [Full Text] [Related]
20. Laparoscopic versus open approach for interval cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced epithelial ovarian cancer: a matched comparative study.
Durán-Martínez M; Gómez-Dueñas G; Rodriguez-Ortíz L; Sanchez-Hidalgo JM; Gordón-Suárez A; Casado-Adam Á; Rufián-Peña S; Valenzuela-Molina F; Rufián-Andujar B; Vázquez-Borrego MC; Romero-Ruiz A; Briceño-Delgado J; Arjona-Sánchez Á
Surg Endosc; 2024 Jan; 38(1):66-74. PubMed ID: 37903884
[TBL] [Abstract] [Full Text] [Related]
[Next]
